Satellos Bioscience (NASDAQ:MSLE) Price Target Raised to $11.00 at HC Wainwright

Satellos Bioscience (NASDAQ:MSLE) had its price target upped by HC Wainwright from $1.20 to $11.00 in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Satellos Bioscience to a “strong sell” rating in a research report on Saturday, March 14th. Weiss Ratings initiated coverage on shares of Satellos Bioscience in a report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a research note on Wednesday, March 11th. They issued an “overweight” rating for the company. Finally, Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $11.00.

Satellos Bioscience Price Performance

Shares of Satellos Bioscience stock opened at $5.91 on Monday. The stock has a market cap of $91.37 million, a PE ratio of -3.81 and a beta of 1.10. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11).

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.